Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(7)
•••
Comment by CCAbbott888on Sep 20, 2019 3:07pm
178 Views
Post# 30149292

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Patent protect for ATE

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Patent protect for ATE
themagicbox wrote:

My concern is around S. Korea rejecting the patent, yet the their intial deal is with them. Secondly, its the true the patent is till 2030, but phase 3 will be about ~3-4 years.So when you do the math it is not a long time horizon to make money. I suspect thats also potentially why they havent been able to have some buy rights (or they are holding on to it for phase 3 results). Even if they have a really strong launch, you're looking at a short lived cash stream especially given the amount money you need to invest in marketing the product.
@themagicbox

Please refer to my earlier post about Antibe's patent in South Korea using the third party link you've provided.  The patent was granted.
 https://stockhouse.com/companies/bullboard?symbol=v.ate&postid=30146852

@MUGMODs
It is possible that somehow themagicbox do not see my post.  Can you help him if that is the case? Thanks very much.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities